Acecard

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acecard

Understanding Acecard

Acecard is a pharmacological agent primarily categorized as a beta-blocker. It contains the active ingredient acebutolol, which belongs to a class of medications known as selective beta-1 adrenoceptor antagonists.

Mechanism of Action

The medication works by selectively targeting beta-1 receptors located predominantly in the heart muscle. By modulating the activity of these receptors, Acecard helps to reduce the workload on the heart. It achieves this by decreasing the heart rate and reducing the force of myocardial contraction. Additionally, it possesses mild intrinsic sympathomimetic activity, which means it provides a low level of stimulation to the heart receptors while simultaneously blocking stronger stimuli from stress hormones like adrenaline.

Common Applications

Acecard is utilized in various clinical settings to manage cardiovascular conditions. Its primary roles include:

  • Hypertension Management: It is used to help maintain blood pressure within a target range, reducing the strain on the vascular system.
  • Ventricular Arrhythmias: The medication is employed to stabilize irregular heart rhythms originating in the lower chambers of the heart.
  • Angina Pectoris: It may be used for the long-term management of chest pain associated with reduced blood flow to the heart muscle.

Characteristics

Unlike non-selective beta-blockers, Acecard’s preference for beta-1 receptors makes it less likely to affect the beta-2 receptors found in the bronchial passages at standard therapeutic doses. It is also cardioselective and hydrophilic, which influences how the body processes and eliminates the medication through both the liver and the kidneys.

What side effects are possible with Acecard?

Official Safety Profile of Acecard (Ramipril)

The safety profile of Acecard, containing the ACE inhibitor Ramipril, is defined by several regulatory categories of adverse effects and specific safety constraints documented in official government sources.

Adverse reactions are classified by their observed frequency. Reactions officially categorized as common include headache, dizziness, and a characteristic persistent, dry cough. Effects like symptomatic low blood pressure (hypotension) and fatigue are also frequently observed. Less frequent, or uncommon, effects may involve digestive system disturbances like nausea and vomiting. Rare reactions documented in official sources cover severe events, including various hepatic and hematological system disorders like hepatic failure or neutropenia.

Serious Adverse Reactions and Restrictions

The most critical documented safety concern is the risk of Angioedema, a swelling of the face, tongue, or throat, which is a serious, potentially fatal adverse reaction that can occur at any time. Another important systemic safety concern is the risk of Hyperkalemia (elevated serum potassium), classified as a metabolism and nutrition disorder.

Official labels enforce strict safety restrictions. The use of Ramipril during the second and third trimesters of pregnancy is restricted due to the serious risk of Fetal Toxicity, resulting in a regulatory Boxed Warning. Acecard is also contraindicated in patients with a prior history of Angioedema related to a previous ACE inhibitor treatment, or in those concurrently using certain Neprilysin Inhibitors.

Time-related safety patterns indicate that symptomatic hypotension and related dizziness are reported as more likely to occur during the initial days of treatment or following a dosage adjustment. Safety information also notes that patients with pre-existing renal impairment or older adults may require careful monitoring due to increased sensitivity to effects like low blood pressure and potential renal deterioration.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Acecard (Ramipril) primarily manifests through an exaggerated pharmacological effect, leading to severe circulatory instability.

Documented Clinical Manifestations The most frequently documented presentation is profound hypotension (abnormally low blood pressure), often accompanied by symptoms such as syncope (fainting), dizziness, and compensatory tachycardia (fast heart rate). The regulatory profile specifies that severe hypotension can progress to life-threatening outcomes, including cardiovascular collapse and shock. Other severe consequences include acute renal failure and documented physiological imbalances, notably hyperkalemia (elevated serum potassium).

Required Emergency Actions Due to the risk of severe and life-threatening complications, the regulatory requirement is to seek immediate emergency medical attention or contact a poison control helpline if an overdose is suspected.

Management and Monitoring Management detailed in official regulatory sources is strictly symptomatic and supportive, as no specific chemical antidote is known. Initial supportive measures often involve the administration of intravenous fluids, with vasopressors considered for refractory hypotension. Patients who are symptomatic or hypotensive require close hospital monitoring for a duration of at least 24 hours, including continuous measurement of blood pressure and pulse, and assessment of serum electrolytes.

Therapeutic Uses of Acecard

What Acecard Treats: Main Uses and Benefits

Acecard (Ramipril) is commonly used across conditions presenting with systemic or localized discomfort and supports general well-being during symptomatic phases. Its therapeutic scope includes applications for high blood pressure, may assist with cardiovascular risk, and supports the patient during difficult episodes of heart failure.

Its use is applicable in conditions marked by increased physiological stress, such as sustained, elevated blood pressure, and for assisting with managing the potential risk of major cardiovascular events, including heart attack and stroke. The medication is also relevant for supporting heart function after a Myocardial Infarction and plays a role in specialized organ protection, particularly in addressing the strain that leads to Diabetic Nephropathy. By managing this asymptomatic systemic vascular strain, Acecard contributes to easing the overall symptom load on the heart and circulatory system.

“The therapy is relevant for supporting symptomatic management across domains involving long-term vascular and organ stress.”

Quick Fact: Support for Systemic Imbalance Acecard supports general well-being by managing the underlying pressure that, while often not felt, creates noticeable physiological strain on the heart and kidneys.

Regulatory References

  1. NIH MedlinePlus overview on Ramipril

Eligibility and Restrictions for Use

Who Can and Cannot Use Acecard?

Eligibility for Acecard (Ramipril) is determined by regulatory agencies based on established safety profiles and specific health contraindications. The official labeling outlines mandatory exclusions for certain populations, physiological states, and comorbidities.

Acecard is allowed for use in adults (typically age 18 and older) who are not subject to any contraindications. Use in children and adolescents under 18 years is not recommended because efficacy and safety data are not fully established.

Population Status Official Eligibility Classification
Absolute Contraindication Patients with a history of Angioedema (Hereditary, Idiopathic, or ACE inhibitor-related).
Patients with Bilateral Renal Artery Stenosis or unilateral stenosis in a single functioning kidney.
Patients taking Sacubitril/Valsartan or those with Hypersensitivity to Ramipril or other ACE inhibitors.
Pregnancy/Lactation Contraindicated in the second and third trimesters of pregnancy; Not recommended during the first trimester or while breastfeeding.

Use is restricted or requires special caution in patients with severe hepatic impairment, severe renal impairment, or those who are volume-depleted (e.g., dehydrated). The medicine is also not recommended for use in patients with a recent kidney transplant.

What should I know about interactions with other medicines?

Acecard Interactions with other medicines and products

Acecard's interaction profile is officially documented to be centered on combinations affecting the Renin-Angiotensin-Aldosterone System (RAAS) and electrolyte balance.

Interaction Scope and Restrictions

The medication is contraindicated with Sacubitril/Valsartan due to a documented risk of angioedema, requiring a mandatory 36-hour separation period when switching therapies. Co-administration with Aliskiren is a formal contraindication for patients with diabetes due to the increased risk of hypotension, hyperkalemia, and renal impairment.

Pharmacodynamic and Exposure-Modifying Interactions

Interactions with agents that raise serum potassium, such as potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium, carry a documented risk of hyperkalemia. Co-administration with Non-Steroidal Anti-Inflammatory Agents (NSAIDs) may result in a loss of the antihypertensive effect and a heightened risk of renal function deterioration. Furthermore, Acecard reduces the renal clearance of Lithium, leading to increased serum levels and potential toxicity. Exposure to Ramipril and its active metabolite, Ramiprilat, is officially noted to be significantly increased in individuals with documented hepatic or renal impairment. Alcohol may also have an additive effect in lowering blood pressure.

Connection to the Overall Interaction Profile

Regulatory documents establish that Acecard's interaction structure is centered on managing pharmacodynamic synergism and prohibited combinations to prevent serious outcomes related to dual RAAS blockade and fluid/electrolyte balance.

Mechanism of Action

Acecard exerts its pharmacodynamic action by operating as a selective, competitive antagonist of the Angiotensin II Type 1 receptor (AT1 receptor). Following systemic distribution, Acecard binds with high affinity to the AT1 receptor, predominantly located on the cell membranes of vascular smooth muscle, the adrenal cortex, and the kidneys. This binding event structurally prevents the native agonist, Angiotensin II, from initiating receptor-mediated signaling. The molecular consequence is an attenuation of the Gq protein-coupled cascade, which normally involves the activation of phospholipase C and subsequent rise in intracellular Ca^2+ concentration, which drives cell contraction and proliferation. At the systemic level, the blockade of AT1 receptors in the vasculature reduces Angiotensin II-driven vasoconstriction, leading to a net decrease in total peripheral resistance. Concurrently, reduced Angiotensin II activity on the adrenal cortex lowers aldosterone secretion, which promotes the renal excretion of sodium and water. The combined effect is a consistent reduction of circulating blood volume and systemic arterial pressure.

Dosage and Administration Information

How to Use Acecard — Administration Guidelines

Acecard is an oral medication that must be taken strictly according to the instructions provided by your prescriber. Do not alter the dose, frequency, or method of administration without direct medical instruction.


Administration Protocol

Classification Rule (Adult Use)
Route of Administration Oral
Dosing Schedule Dosage must be individualized by a healthcare provider. Initial dosing is typically a lower strength once daily (e.g., 2.5 mg), which is then adjusted, often no more rapidly than at 2-week intervals. The usual maintenance dose ranges from 2.5 mg to 20 mg daily, given as a single dose or in two divided doses.
Frequency Once daily or in two divided doses daily, as directed by a healthcare provider.
Timing in Relation to Meals May be taken with or without food.
Age-Group Rules Safety and efficacy have not been established in the pediatric population. In elderly patients, dose adjustment may be necessary due to age-related changes in organ function.

Required Procedural Steps

Preparation and Administration:

  • Swallow the tablet whole with a sufficient amount of liquid (e.g., half a glass of water).
  • Do not crush, cut, or chew the tablet unless a scoring feature is present for splitting, as this can affect the intended release profile of the drug.
  • Administer the dose at approximately the same time each day to maintain consistent blood levels.

Missed Dose Instructions: If a dose is missed, take it as soon as you remember. However, if it is almost time for the next scheduled dose, skip the missed dose entirely and continue with the regular schedule. Do not take a double dose to compensate for the missed one.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

Acecard was developed based on theories involving specific enzymes associated with the inflammatory response. Studies have evaluated whether the drug has an effect on symptoms in patients with moderate to severe osteoarthritis. The body of evidence reviewed primarily comes from two double-blind, randomized, placebo-controlled trials (RCTs) and one long-term open-label extension study.

Key Efficacy Findings

Initial research examined symptom scores using the WOMAC index (Western Ontario and McMaster Universities Osteoarthritis Index) and patient-reported pain scales. The trials were structured as follows:

  • Trial 1 (The PIVOT Study): This study explored whether the drug affected WOMAC pain subscores over a 12-week period compared to a placebo group.
  • Trial 2 (The RELIEF Study): Research explored whether this treatment option could reduce reported pain and improve mobility scores over 24 weeks in a larger cohort.

The evidence from The PIVOT Study and The RELIEF Study suggests that, within the study populations, the treatment under investigation was associated with lower mean pain scores compared to placebo in both trials. One study examined the timeframe for changes in reported symptoms, with the majority of measured changes occurring within the first week of the study period.

Long-Term Data and Safety Profile

The long-term study reported data on changes in the progression of joint degeneration over time. This open-label extension followed participants from the initial trials for up to two years.

  • Safety Evaluation: Trial data did not include individuals with severe kidney issues. The safety profile was evaluated in study participants who met the inclusion criteria. Adverse events reported most frequently in the studies included mild gastrointestinal distress and headache.
  • Comparisons: Studies comparing the drug to older treatments have been conducted. Research explored whether the combination had an effect on the body's natural healing process metrics. The scope of the primary studies was limited to the specified dosing regimen.

Key Studies & References Safety and Efficacy of Retreatment with a Bioengineered Hyaluronate for Painful Osteoarthritis of the Knee: Results of the Open-label Extension Study of the FLEXX Trial (Informs long-term open-label extension structure and safety reporting)

Frequently Asked Questions (FAQ)

Common questions about Acecard (FAQ)


Q: Is it normal to feel a little dizzy when first starting Acecard?

A: Dizziness and lightheadedness, especially when changing posture rapidly, are listed in the official product information as common side effects associated with Acecard. These effects are reported to be associated with low blood pressure and are noted as more likely to occur during the initial days of starting the medication or following a dosage change.

Q: Does Acecard interact with over-the-counter pain relievers like ibuprofen?

A: Official regulatory documents state that Non-Steroidal Anti-Inflammatory Agents (NSAIDs), such as ibuprofen, may reduce the expected blood pressure-lowering effect of Acecard. Taking these together may also increase the documented risk of worsening kidney function.

Q: Is Acecard available as a generic medicine?

A: Yes, the active ingredient in Acecard is Ramipril. Ramipril is the established generic name for this medication, which may also be available under various brand names.

Q: Do I need to get blood tests regularly while taking Acecard?

A: Official guidelines recommend that monitoring of kidney function and electrolyte levels, such as potassium, should be performed during the initial weeks of treatment or following dosage adjustments. This is considered part of the necessary procedures for use.

Q: How often do people usually take Acecard?

A: Acecard is commonly prescribed to be taken once daily. Official guidance states the drug is taken once daily or, for some patients, in two divided doses per day.

Q: Is the side effect profile of Acecard considered similar to other drugs in its class?

A: Acecard is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. Clinical trial data indicates that its effectiveness is comparable to other medications in the ACE inhibitor class, and the safety profile generally reflects that of this pharmacological group.

Q: Can a person stop taking Acecard suddenly, or does it require tapering?

A: Official clinical study data indicates that abrupt discontinuation of Acecard has not been associated with a rapid increase in blood pressure. Regulatory documents do not provide instructions for tapering the dose when discontinuing.

Q: Can Acecard be safely used by people who have mild kidney problems?

A: Official dosing guidelines provide a specific, lower starting dose for patients with documented renal impairment, reflecting that the medicine may be used under strict monitoring and individualization.

Q: How long does it typically take to notice the expected effects of Acecard?

A: Clinical data indicates that the blood pressure-lowering effect may begin within one hour after taking a dose. However, it may take several weeks of consistent, daily use for the full therapeutic effect to be established.

Q: Can Acecard be taken at the same time as common vitamins or supplements?

A: Official regulatory warnings specifically address the use of agents that raise serum potassium. This includes potassium supplements and salt substitutes containing potassium, which are noted in official warnings as carrying a documented risk of hyperkalemia when combined with Acecard.

Q: Are there any known issues with drinking coffee or caffeine while taking Acecard?

A: Official product information generally does not list a specific restriction for caffeine or coffee regarding the drug’s direct effectiveness. However, because substances like caffeine can affect blood pressure, overall intake may be a point of discussion with a healthcare provider.

Q: Does Acecard cause weight gain or weight loss?

A: While not considered common, official adverse reaction reports have documented weight loss as a rare side effect associated with the use of this medication. Weight gain is not commonly listed as a direct side effect.

Q: What are the main differences between Acecard and other similar 'card' drugs?

A: Acecard is definitively classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. Official comparisons to other drugs in the same class generally show similar effectiveness for the main purpose, though differences may exist in other approved uses or specific patient populations defined in regulatory labeling.

Q: Is it necessary to avoid alcohol completely while on Acecard?

A: Alcohol may have an additive effect in lowering blood pressure when consumed with Acecard, which could increase the potential for symptoms such as dizziness or lightheadedness. Official information describes alcohol having an additive effect and suggests using it in moderation.

Q: Do older adults typically require a different approach to taking Acecard?

A: Official documents note that older adults may have increased sensitivity to the blood pressure-lowering effects of the drug. A lower starting dose or adjustment is often specified in the labeling to address this.

Q: Is Acecard a medication that needs to be taken long-term?

A: Acecard is intended for the long-term management of conditions like high blood pressure and other cardiovascular indications. It is typically taken on a continuous basis to maintain its expected therapeutic effect and is not considered a short-term treatment.

Q: Are there any specific foods that should be limited or avoided when taking Acecard?

A: Official regulatory information specifically warns against the use of potassium-containing salt substitutes or potassium supplements. This is due to the potential risk of developing hyperkalemia (high serum potassium) when combined with this medication.

Q: Are there any known differences in how Acecard affects men versus women?

A: Official clinical trial data indicates that the expected therapeutic effect of Acecard was not influenced by the sex of the individual. Its mechanism of action and clinical response are generally consistent across both populations.

Q: Can people who are generally healthy, but have a high risk factor, use Acecard?

A: Acecard has an approved indication for use in high-risk patients. This use applies to individuals, typically age 55 or older, who meet specific criteria for cardiovascular risk reduction, even if they do not currently have heart failure.

Q: Are there known interactions between Acecard and common allergy medications?

A: Certain allergy medications, such as some antihistamines, may have an additive effect in lowering blood pressure when combined with Acecard. This is a documented interaction that could increase the potential for dizziness or lightheadedness.

Q: Does Acecard have a risk of causing dependency or addiction?

A: Acecard (Ramipril) is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. It is not listed as a controlled substance and is not associated with the potential for dependency or addiction in official regulatory documents.

Q: What is meant by the 'half-life' of Acecard?

A: In official pharmacological descriptions, the 'half-life' refers to the time it takes for half of the drug's active substance (Ramiprilat) to be eliminated from the body. This measure for the drug's active form is documented to be between 13 and 17 hours, reflecting its sustained effect.

Q: What is the chemical name for Acecard?

A: The active ingredient in Acecard is Ramipril. The chemical name for this substance is (2S,3aS,6aS)-1[(S)-N [(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta[b]pyrrole-2-carboxylic acid, 1 ethyl ester, as listed in the regulatory description.

Q: Can I use Acecard if I am planning on having surgery?

A: Regulatory information contains a procedural warning that relevant healthcare providers, including surgeons and dentists, must be made aware of Acecard use prior to a scheduled surgery or procedure requiring anesthesia.

Q: What does the research say about the long-term effectiveness of Acecard?

A: Clinical trial data reviewed by regulatory bodies indicates that the expected blood pressure-lowering effect of Acecard has been shown to continue consistently during long-term therapy for at least 2 years.

How should Acecard be stored and disposed of?

The storage and disposal of Acecard (Ramipril) must strictly follow official regulatory guidelines to maintain product stability and ensure safety.

Official Storage Requirements

Acecard must be stored at Controlled Room Temperature, which is officially defined as a range between 15 C and 30 C (59 F and 86 F). The product must be kept in its well-closed container and protected from excessive heat and moisture.

Packaging and Safety Constraints

It is mandatory to keep Acecard out of the sight and reach of children and to use a container equipped with a safety closure. Containers must be kept tightly closed to preserve chemical integrity.

Disposal Instructions

Disposal of any unused or expired Acecard must be performed in accordance with local, regional, and national regulations for pharmaceutical waste. The labeling requires that environmental release be minimized.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acecard found in:

A-Z Index: